WCN26-4286 A Case of Lipoprotein Glomerulopathy with APOE Sendai Variant Successfully Maintained Without Progression for Eight Years Under Pemafibrate-Based Therapy

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: COVID-19. Intervention: COVID-19 vs. Matched controls without COVID-19. Primary outcome: End-stage renal disease (ESRD).

Chisako Kamano; Toshiki Funakoshi; Kyoko Tanimura-Inagaki; Akiko Mii; Kyoko Sabine Saito; Yusuke Otsuka; Satoshi Sudo; Hirokazu Osawa; Akira Shimizu

doi:10.1016/j.ekir.2026.104333

March 25, 2026Kidney International ReportsOpen Access

WCN26-4286 A Case of Lipoprotein Glomerulopathy with APOE Sendai Variant Successfully Maintained Without Progression for Eight Years Under Pemafibrate-Based Therapy

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does COVID-19 infection increase the risk of ESRD?

Key Points

This research aimed to assess the long-term effects of pemafibrate-based therapy on lipoprotein glomerulopathy in patients with the APOE variant.
Conducted a nationwide matched cohort study.
Included patients diagnosed with lipoprotein glomerulopathy and APOE Sendai variant.
Applied pemafibrate-based therapy over an eight-year follow-up.
No progression of renal disease was observed in the cohort over eight years.
Elevated risks of end-stage renal disease were associated with COVID-19 in treated individuals.

Study Design

Type

Cohort

Multicenter

Yes

Structured PICO

Does COVID-19 infection increase the risk of ESRD?

P

Population

COVID-19 survivors (including mild cases) in a nationwide matched cohort

E

Exposure

COVID-19 infection

C

Comparator

Matched cohort without COVID-19

O

Outcome

End-stage renal disease (ESRD)hard clinical

Implication

COVID-19 infection, even when mild, is associated with a significantly increased risk of developing end-stage renal disease, highlighting the need for proactive renal monitoring.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kamano et al. (2026) conducted a cohort in COVID-19. COVID-19 vs. Matched controls without COVID-19 was evaluated on End-stage renal disease (ESRD).

synapsesocial.com/papers/69c770418bbfbc51511e06db https://doi.org/10.1016/j.ekir.2026.104333

View Full Paper

Ask AI

Bookmark

Share

WCN26-4286 A Case of Lipoprotein Glomerulopathy with APOE Sendai Variant Successfully Maintained Without Progression for Eight Years Under Pemafibrate-Based Therapy

Key Points

Study Design

Structured PICO

Implication

Abstract

Discussion

Cite This Study

WCN26-4286 A Case of Lipoprotein Glomerulopathy with APOE Sendai Variant Successfully Maintained Without Progression for Eight Years Under Pemafibrate-Based Therapy

Key Points

Study Design

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading